Search results for "drug evaluation"

showing 10 items of 188 documents

Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia

2004

Oxygen free radicals have been involved in the pathophysiology of cerebral ischemia, especially after spontaneous or thrombolytic reperfusion. In this study with rats, we have combined a severe focal ischemic insult (2 h) and a prolonged reperfusion time (7 days) to assess the possible sustained neuroprotective effect of ebselen (10 or 100 mg/kg), a small, lipophilic organoselenium compound which mimics glutathione peroxidase. Parietal cortical perfusion was measured by laser-Doppler flowmetry, and focal cerebral ischemia was carried out by the intraluminal thread method. We have measured plasma selenium levels, brain reduced glutathione levels, as a marker of oxidative stress, and infarct …

AzolesMaleTime FactorsCentral nervous systemDrug Evaluation PreclinicalIschemiaAdministration OralIsoindolesPharmacologymedicine.disease_causeNeuroprotectionDrug Administration ScheduleBrain IschemiaSeleniumchemistry.chemical_compoundOrganoselenium CompoundsAnimalsMedicineRats WistarBrain ChemistryPharmacologychemistry.chemical_classificationbusiness.industryEbselenCerebral infarctionGlutathione peroxidaseBody WeightBrainInfarction Middle Cerebral ArteryGlutathionemedicine.diseaseGlutathioneRatsOxidative Stressmedicine.anatomical_structurechemistrySpainAnesthesiaReperfusionReactive Oxygen SpeciesbusinessOxidative stressEuropean Journal of Pharmacology
researchProduct

Discovery of 5-benzyl-3-phenyl-4,5-dihydroisoxazoles and 5-benzyl-3-phenyl-1,4,2-dioxazoles as potent firefly luciferase inhibitors.

2013

Luciferase reporter assays are commonly used in high-throughput screening methods. Here, we report new firefly luciferase (FLuc) inhibitors based on 5-benzyl-3-phenyl-4,5-dihydroisoxazoles and 5-benzyl-3-phenyl-1,4,2-dioxazoles, which showed up as "false positives" in a luciferase reporter gene-based assay for nuclear receptor antagonists. The inhibition was shown to be noncompetitive for both natural enzyme substrates (d-luciferin and ATP) and selective to FLuc and proven to arise from a direct interaction between the enzyme and the inhibitor. Of the 63 evaluated compounds, 28 showed significantly better inhibition potency than the well-known inhibitor resveratrol (IC(50) = 59 nM), with fi…

AzolesModels MolecularMagnetic Resonance SpectroscopyStereochemistryDrug Evaluation PreclinicalResveratrolCell Linechemistry.chemical_compoundInhibitory Concentration 50Drug DiscoveryScreening methodIc50 valuesPotencyAnimalsLuciferaseEnzyme InhibitorsLuciferasesIC50ta116chemistry.chemical_classificationFirefliesEnzymechemistryNuclear receptorBiochemistryMolecular MedicineJournal of medicinal chemistry
researchProduct

Solution versus Fluorous versus Solid-Phase Synthesis of 2,5-Disubstituted 1,3-Azoles. Preliminary Antibacterial Activity Studies

2009

A small library of compounds with an oxa(thia)zole scaffold and structural diversity in both positions 2 and 5 has been synthesized. Double acylation of a protected glycine affords intermediate α-amido-β-ketoesters, which in turn can be dehydrated to afford 1,3-oxazoles or reacted with Lawesson’s reagent to furnish 1,3-thiazoles. This procedure was designed with its adaptation to fluorous techniques in mind. Thus, when a protected glycine with a fluorous tag in the ester moiety is used as a starting material, the synthesis can be easily completed without column chromatography purification of intermediate compounds with good to excellent yields, thus affording a suitable entry to the prepara…

AzolesStaphylococcus aureusANTIBACTERIAL ACTIVITYDrug Evaluation PreclinicalMicrobial Sensitivity TestsChemical synthesisSmall Molecule LibrariesAcylationchemistry.chemical_compoundSolid-phase synthesisColumn chromatographyAZOLESOrganic chemistryMoietyAntibacterial agentChemistryOrganic ChemistryCiencias QuímicasFLUOROUSCombinatorial chemistryAnti-Bacterial AgentsSolutionsQuímica OrgánicaMolecular ProbesSOLID-PHASELawesson's reagentAntibacterial activityCIENCIAS NATURALES Y EXACTAS
researchProduct

Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8ΔCTE inhibitors as potential therapeutics for leishmaniasis

2018

Abstract: Chemotherapy is currently the only effective approach to treat all forms of leishmaniasis. However, its effectiveness is severely limited due to high toxicity, long treatment length, drug resistance, or inadequate mode of administration. As a consequence, there is a need to identify new molecular scaffolds and targets as potential therapeutics for the treatment of this disease. We report a small series of 1,2‐substituted‐1H‐benzo[d]imidazole derivatives (9ad) showing affinity in the submicromolar range (Ki = 0.150.69 μM) toward Leishmania mexicanaCPB2.8ΔCTE, one of the more promising targets for antileishmanial drug design. The compounds confirmed activity in vitro against intrace…

BenzimidazoleCell SurvivalIn silicoLeishmania mexicanaAntiprotozoal AgentsDrug Evaluation PreclinicalProtozoan ProteinsDrug resistanceCysteine Proteinase InhibitorsPharmacologyAntileishmanial agents Benzimidazole derivatives Docking studies In silico profiling Leishmania mexicanaCPB2.8 Biochemistry Molecular Medicine01 natural sciencesBiochemistryLeishmania mexicanaCell LineInhibitory Concentration 50chemistry.chemical_compoundCysteine ProteasesDrug DiscoverymedicineHumansAmastigoteLeishmaniasisBiologyEnzyme AssaysPharmacologyBinding Sitesbiology010405 organic chemistryChemistryPharmacology. TherapyOrganic ChemistryHydrogen BondingLeishmaniasisbiology.organism_classificationmedicine.diseaseLeishmaniaProtein Structure Tertiary0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryChemistryMolecular MedicineBenzimidazolesHuman medicineLeishmania infantumChemical biology and drug design
researchProduct

COX-1/COX-2 inhibitors based on the methanone moiety

2002

This paper focuses on the synthesis and the in vitro testing of dual COX-1/COX-2 inhibitors. Starting from structures of non-steroidal anti-inflammatory drugs (NSAIDs) the diaryl methanone element was chosen as a lead. Modifications were carried out on this scaffold to obtain potent inhibitors of the COX enzymes. The N-(2-aroylphenyl)sulphonamides and -amides were studied in detail, and to consolidate the data evaluated the corresponding 3- and 4-regioisomers were also investigated. The potency and the enzyme selectivity were varied by structural modifications of the lead.

Blood PlateletsStereochemistrymedicine.drug_classDrug Evaluation PreclinicalCarboxamideIsozymeChemical synthesisStructure-Activity RelationshipOxazinesDrug DiscoverymedicineAnimalsPotencyMoietyCyclooxygenase InhibitorsPharmacologychemistry.chemical_classificationCyclooxygenase 2 InhibitorsMolecular StructurebiologyChemistryAnti-Inflammatory Agents Non-SteroidalOrganic ChemistryGeneral MedicineIn vitroIsoenzymesEnzymeCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme inhibitorCyclooxygenase 1biology.proteinEuropean Journal of Medicinal Chemistry
researchProduct

In-vitro test system for the evaluation of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibitors based on a single HPLC run with UV detect…

2001

Objective and Design: The aim of this study was to develop a new, whole-cell test system which is easy to handle and requires a standard equipment for the parallel screening of COX-1 and COX-2 inhibitors.¶Materials: Bovine aortic endothelial cells (BAECs).¶Treatment and methods: Unstimulated bovine aortic coronary endothelial cells (BAECs) were used as a source of COX-1 and BAECs pretreated with ASA (100 μM) and activated with phorbol myristate acetate (PMA) were used as a source of COX-2. The time- and concentration-dependent induction of COX-2 expression in the BAECs was evaluated by a kinetic profile (HPLC analysis) and detected by Western-Blot analysis using polyclonal antibodies agains…

Blotting WesternImmunologyDrug Evaluation PreclinicalAorta ThoracicIn Vitro TechniquesHigh-performance liquid chromatographyLipoxygenaseDiclofenacmedicineAnimalsCyclooxygenase InhibitorsLipoxygenase InhibitorsIC50Chromatography High Pressure LiquidPharmacologyCyclooxygenase 2 InhibitorsbiologyChemistryMolecular biologyIsoenzymesKineticsMeloxicamBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesPolyclonal antibodiesCyclooxygenase 1biology.proteinTetradecanoylphorbol AcetateAceclofenacCattleSpectrophotometry UltravioletEndothelium VascularCyclooxygenasemedicine.drugInflammation Research
researchProduct

A Neuroprotective Function for the Hematopoietic Protein Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)

2007

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic cytokine responsible for the proliferation, differentiation, and maturation of cells of the myeloid lineage, which was cloned more than 20 years ago. Here we uncovered a novel function of GM-CSF in the central nervous system (CNS). We identified the GM-CSF α-receptor as an upregulated gene in a screen for ischemia-induced genes in the cortex. This receptor is broadly expressed on neurons throughout the brain together with its ligand and induced by ischemic insults. In primary cortical neurons and human neuroblastoma cells, GM-CSF counteracts programmed cell death and induces BCL-2 and BCL-Xl expression in a dose- a…

Brain InfarctionMaleProgrammed cell deathTime FactorsMyeloidmedicine.medical_treatmentDrug Evaluation Preclinicalbcl-X ProteinApoptosisBiologyNeuroprotectionBrain IschemiaPhosphatidylinositol 3-KinasesmedicineAnimalsHumansMyeloid CellsRats Long-EvansRats WistarProtein kinase BCell ProliferationCerebral CortexNeuronsDose-Response Relationship DrugGrowth factorGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationNeurodegenerative DiseasesRatsUp-RegulationCell biologyDisease Models AnimalHaematopoiesisNeuroprotective Agentsmedicine.anatomical_structureGranulocyte macrophage colony-stimulating factorNeurologyBlood-Brain BarrierReceptors Granulocyte-Macrophage Colony-Stimulating FactorImmunologyNeurology (clinical)Signal transductionCardiology and Cardiovascular MedicineProto-Oncogene Proteins c-aktSignal Transductionmedicine.drugJournal of Cerebral Blood Flow & Metabolism
researchProduct

Drug Screening Boosted by Hyperpolarized Long-Lived States in NMR

2014

International audience; : Transverse and longitudinal relaxation times (T1ρ and T1 ) have been widely exploited in NMR to probe the binding of ligands and putative drugs to target proteins. We have shown recently that long-lived states (LLS) can be more sensitive to ligand binding. LLS can be excited if the ligand comprises at least two coupled spins. Herein we broaden the scope of ligand screening by LLS to arbitrary ligands by covalent attachment of a functional group, which comprises a pair of coupled protons that are isolated from neighboring magnetic nuclei. The resulting functionalized ligands have longitudinal relaxation times T1 ((1) H) that are sufficiently long to allow the powerf…

BromidesMagnetic Resonance SpectroscopyStereochemistryDrug Evaluation PreclinicalThiophenesLigands010402 general chemistry01 natural sciencesBiochemistrydynamic nuclear polarizationchemistry.chemical_compoundNMR spectroscopyCatalytic DomainDrug DiscoveryGeneral Pharmacology Toxicology and PharmaceuticsPharmacologySpins[CHIM.ORGA]Chemical Sciences/Organic chemistry010405 organic chemistryDrug discoveryOrganic ChemistryRelaxation (NMR)ProteinsNuclear magnetic resonance spectroscopyFull PapersLigand (biochemistry)0104 chemical sciencesCrystallographychemistryCovalent bondlong-lived statesExcited stateFunctional groupMolecular MedicineChemMedChem
researchProduct

Topical treatment with a two-component gel releasing nitric oxide cures C57BL/6 mice from cutaneous leishmaniasis caused by Leishmania major.

2016

C57BL/6medicine.medical_specialty030231 tropical medicineDrug Evaluation PreclinicalLeishmaniasis CutaneousTopical treatmentDermatologyPharmacologyAdministration CutaneousBiochemistryNitric oxide030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCutaneous leishmaniasismedicineAnimalsLeishmania majorNitric Oxide DonorsMolecular BiologyLeishmania majorbiologybusiness.industryLeishmaniasisbiology.organism_classificationmedicine.diseaseDermatologyMice Inbred C57BLchemistrybusinessGelsExperimental dermatology
researchProduct

Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pande…

2020

Background Starting December 2019, mankind faced an unprecedented enemy, the COVID-19 virus. The world convened in international efforts, experiences and technologies in order to fight the emerging pandemic. Isolation, hygiene measure, diagnosis, and treatment are the most efficient ways of prevention and intervention nowadays. The health organizations and global care systems screened the available resources and offered recommendations of approved and proposed medications. However, the search for a specific selective therapy or vaccine against COVID-19 remains a challenge. Methods A literature search was performed for the screening of natural and derived bio-active compounds which showed po…

COVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug Evaluation PreclinicalPharmaceutical ScienceAntiviral AgentsArticle03 medical and health scienceschemistry.chemical_compoundClinical trials0302 clinical medicineTocilizumabChloroquineDrug DiscoveryPandemicmedicineHumansAntiviralPandemics030304 developmental biologyPharmacologyBiological ProductsClinical Trials as TopicNatural products0303 health sciencesProtectionMolecular StructureTraditional medicineSARS-CoV-2business.industryCOVID-19LycorineFingolimodCOVID-19 Drug TreatmentClinical trialConessineComplementary and alternative medicinechemistry030220 oncology & carcinogenesisMolecular MedicinePatentPlant Preparationsbusinessmedicine.drugPhytomedicine
researchProduct